Turoctocog

Turoctocog (also known as NovoEight) is a recombinant factor VIII used for the treatment and prevention of bleeding in patients with Hemophilia A. It is produced by Novo Nordisk and was approved by the FDA in 2013.

Mechanism of Action

Turoctocog works by replacing the missing Factor VIII, a clotting factor necessary for the blood to clot. This helps to prevent or control bleeding episodes.

Uses

Turoctocog is used to treat and prevent bleeding in people with Hemophilia A. It can be used in all age groups and for all types of bleeds.

Side Effects

Common side effects of Turoctocog include rash, itching, and reactions at the injection site. Serious side effects may include allergic reactions, formation of antibodies (inhibitors) to factor VIII, and blood clots.

Administration

Turoctocog is administered by intravenous injection. The dosage and frequency of administration depend on the severity of the Hemophilia A, the location and extent of bleeding, and the patient's clinical condition.

See Also

• Hemophilia A
• Factor VIII
• Novo Nordisk

References

Turoctocog Resources
Latest articles Most recent articles Ongoing trials	Wikipedia